Home > Healthcare > Pharmaceuticals > Vaccines > Tetanus Toxoid Vaccine Market
Tetanus Toxoid Vaccine Market Size
- Report ID: GMI8301
- Published Date: Feb 2024
- Report Format: PDF
Tetanus Toxoid Vaccine Market Size
Tetanus Toxoid Vaccine Market size was valued at USD 5 billion in 2023 and is estimated to grow at over 5.8% CAGR from 2024 to 2032. Tetanus toxoid vaccine, also known simply as tetanus vaccine, is a type of vaccine used to prevent tetanus, a serious bacterial infection caused by the bacterium Clostridium tetani. The tetanus toxoid vaccine works by stimulating the immune system to produce antibodies against the tetanus toxin. These antibodies help to neutralize the toxin and prevent the development of tetanus infection if exposed to the bacterium in the future.
The escalating incidence of tetanus and diphtheria in several countries is significantly impacting the market on multiple fronts. With the rise in tetanus and diphtheria cases, there's a heightened demand for vaccines to prevent these diseases. This surge in demand directly affects the tetanus toxoid vaccine market, stimulating vaccine manufacturers to ramp up production to meet the growing needs of affected regions. According to a World Health Organization (WHO) in 2022, approximately 84% of children globally received the recommended three doses of diphtheria-tetanus-pertussis (DTP) vaccine.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Tetanus Toxoid Vaccine Market Size in 2023: | USD 5 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 5.8% |
| 2024 – 2032 Value Projection: | USD 8.2 Billion |
| Historical Data for: | 2018 – 2023 |
| No. of Pages: | 145 |
| Tables, Charts & Figures: | 219 |
| Segments covered: | Vaccine Type, Age Group, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Tetanus Toxoid Vaccine Market Scope
